Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Intellia Therapeutics, Inc. - Common Stock
(NQ:
NTLA
)
13.63
+1.18 (+9.47%)
Streaming Delayed Price
Updated: 12:10 PM EDT, Apr 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
3 Biotech Stocks That Could Benefit from the Patent Cliff
↗
April 27, 2026
Via
MarketBeat
Topics
Intellectual Property
Top movers in Friday's after hours session
↗
April 24, 2026
Via
Chartmill
2 Healthcare Stocks to Buy and 1 to Approach With Caution
↗
April 15, 2026
Recent performances don't tell the whole story.
Via
The Motley Fool
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
↗
March 08, 2026
This run could be short-lived.
Via
The Motley Fool
Topics
Death
Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones
↗
February 26, 2026
Via
Chartmill
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
March 03, 2026
The growth investor kicked off this week by buying up some hard-hit stocks.
Via
The Motley Fool
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
March 03, 2026
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Did NTLA Stock Jump 10% In Pre-Market Today?
↗
March 02, 2026
The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.
Via
Stocktwits
Intellia (NTLA) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
Intellia (NTLA) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
↗
February 07, 2026
Will this biotech's innovative platform finally pay off?
Via
The Motley Fool
NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About?
↗
January 27, 2026
The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total...
Via
Stocktwits
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today
↗
January 16, 2026
Via
Stocktwits
Topics
Stocks
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD
↗
January 16, 2026
ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
↗
January 12, 2026
Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
↗
December 29, 2025
Don't get too excited about their prospects.
Via
The Motley Fool
Topics
Death
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
↗
December 02, 2025
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.
Via
Investor's Business Daily
Intellia (NTLA) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Intellia (NTLA) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From
MarketNewsUpdates.com
Via
GlobeNewswire
2 Beaten-Down Stocks to Avoid Right Now
↗
November 15, 2025
There might be plenty more downside for these biotechs.
Via
The Motley Fool
Topics
Death
This Bath & Body Works Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
↗
November 12, 2025
Via
Benzinga
This SPS Commerce Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
↗
November 11, 2025
Via
Benzinga
What 21 Analyst Ratings Have To Say About Intellia Therapeutics
↗
November 11, 2025
Via
Benzinga
Why Gene-Editing Giants Crispr And Intellia Just Surged
↗
November 10, 2025
The companies are working on one-and-done treatments for diseases tied to genetic problems.
Via
Investor's Business Daily
Topics
Death
12 Health Care Stocks Moving In Friday's Intraday Session
↗
November 07, 2025
Via
Benzinga
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies
↗
November 07, 2025
The company remains confident in its other gene-editing product, which would treat a swelling disorder.
Via
Investor's Business Daily
Topics
Death
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
↗
November 07, 2025
Wall Street may be overestimating these companies' potential.
Via
The Motley Fool
Discover the top movers in Friday's pre-market session.
↗
November 07, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 07, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
